| Execution period | FY 2026-27 |
|---|
BSE filing, NSE: PHARMAID. Summary written from the filing by ALFA Finder's alert engine.
Pharmaids Pharmaceuticals Ltd: key numbers
- Share price
- ₹28.42
- Market cap
- ₹100.2 Cr
- Revenue (annual)
- ₹27.88 Cr
- Net profit (annual)
- ₹-11.72 Cr
- P/E (TTM)
- -22.0×Sector 48.7×
- Promoter holding
- 32.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Pharmaids Pharmaceuticals Ltd
All →Pharmaids Pharmaceuticals Other Announcement
Pharmaids Pharmaceuticals Limited filed its quarterly Regulation 74(5) compliance certificate from its Registrar and Share Transfer Agent confirming the dematerialization of shares.
Pharmaids Pharmaceuticals Legal & Regulatory
Pharmaids Pharmaceuticals filed legal complaints against Anugraha Chemicals for dishonoured cheques totalling ₹2.63 Crore in outstanding dues from a disinvestment agreement.
- Value
- ₹2.63 Cr
Pharmaids Pharmaceuticals Annual General Meeting
Pharmaids Pharmaceuticals held its 37th AGM via video conference on 11 Sept 2026. Four resolutions including adoption of FY26 financials and related-party-transaction approvals were tabled.
Pharmaids Pharmaceuticals Promoter Buying (Off-Market)
KMP Prasanna Subramanya Bhat acquired 17,291 shares of Pharmaids Pharmaceuticals Ltd via a gift from an immediate relative. This off-market transfer is an insider disclosure.
- Promoter stake change
- +0.04%
Pharmaids Pharmaceuticals Annual General Meeting
Pharmaids Pharmaceuticals Limited has issued the notice for its 37th Annual General Meeting, scheduled for September 11, 2026, along with the Annual Report for 2025-26.
Pharmaids Pharmaceuticals Q1 FY27 Results: Net Profit ₹1.9 Cr, Down 64.2% YoY
Pharmaids Pharmaceuticals Ltd reported revenue from operations of ₹4.1 Cr (-38.8% YoY) and net profit of ₹1.9 Cr (-64.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.9 Cr · -64.2% YoY
Other other announcement announcements
All →STL Networks Other Announcement
The Monitoring Agency reported Rs. 2 Crore utilization of Preferential Issue proceeds, with no deviations from objects. The report covers the quarter ending September 30, 2026.
HEG Advanced Materials Other Announcement
HEG Advanced Materials Limited has intimated the exchange regarding the change of its Corporate Identification Number (CIN) following an approved scheme of arrangement.
Sanofi India Other Announcement
Sanofi India issued a communication regarding Tax Deduction at Source (TDS) for the interim dividend declared for FY 2026. Shareholders must update details by November 5, 2026.
Visaka Industries Other Announcement
Visaka Industries informed the exchange about sending reminder letters to shareholders regarding the compulsory transfer of unclaimed dividends and equity shares to the IEPF account.
Arvaya Healthcare Other Announcement
Arvaya Healthcare filed its quarterly shareholding pattern under Regulation 31(1)(c). The filing reports routine ownership breakdowns with no transaction.
AYM Syntex Other Announcement
AYM Syntex's board appointed BSR & Co. LLP as statutory auditor for five years, subject to shareholder approval. Routine auditor appointment; no monetary value involved.
- Execution
- Five consecutive years, from the conclusion of the 44th AGM to the conclusion of the 49th AGM